
Optomed Q2 - Soft Q2 sales raises the stakes for H2 recovery

Redeye provides an update following Optomed's Q2 2025 report. Sales came in below our expectations, and we had anticipated a more pronounced impact from the Aurora AEYE camera. As a result, we have made downward adjustments to our sales estimates, leading to an updated fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Optomed Q2 - Soft Q2 sales raises the stakes for H2 recovery